CDTX

About Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.

CEO: Jeffrey L. Stein
IPO Date: Apr 15, 2015

Market Data

Open: $221.38
High: $221.38
Low: $221.38
Volume: 2.7M
52W High: $221.42
52W Low: $15.22

Valuation

Market Cap: $5.6B
Enterprise Value: $5.3B

Financials

Free Cash Flow: $-177M
Revenue: $1.3M
Net Income: $-170M
Cash: $190M
Debt: $3.6M

Events

EarningsNov 6

EPS est. -1.34 · actual -1.43